Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy

References

[1] Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938–45.10.1016/j.jacc.2014.06.1167Suche in Google Scholar

[2] Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115:155–62.10.1159/000265166Suche in Google Scholar

[3] Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213–25.10.1016/j.yjmcc.2012.03.006Suche in Google Scholar

[4] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495–522.10.1007/400_2007_049Suche in Google Scholar

[5] Delhanty PJ, Sun Y, Visser JA, van Kerkwijk A, Huisman M, van Ijcken WF, et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One 2010;5:e11749.10.1371/journal.pone.0011749Suche in Google Scholar

[6] Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004;110:3674–9.10.1161/01.CIR.0000149746.62908.BBSuche in Google Scholar

[7] Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol 2012;59:8–13.10.1016/j.jjcc.2011.11.002Suche in Google Scholar

[8] Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 2004;43:165–70.10.1097/00005344-200402000-00001Suche in Google Scholar

[9] Khatib MN, Simkhada P, Gode D. Cardioprotective effects of ghrelin in heart failure: from gut to heart. Heart Views 2014;15:74–6.10.4103/1995-705X.144792Suche in Google Scholar

[10] Dhein S, Polontchouk L, Salameh A, Haefliger JA. Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40. Biol Cell 2002;94:409–22.10.1016/S0248-4900(02)00018-7Suche in Google Scholar

[11] Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 2008;80:9–19.10.1093/cvr/cvn133Suche in Google Scholar PubMed PubMed Central

[12] Dang X, Doble BW, Kardami E. The carboxy-tail of connexin-43 localizes to the nucleus and inhibits cell growth. Mol Cell Biochem 2003;242:35–8.10.1007/978-1-4757-4712-6_5Suche in Google Scholar

[13] Boengler K, Dodoni G, Rodriguez-Sinovas A, Cabestrero A, Ruiz-Meana M, Gres P, et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 2005;67:234–44.10.1016/j.cardiores.2005.04.014Suche in Google Scholar PubMed

[14] Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000;101:547–52.10.1161/01.CIR.101.5.547Suche in Google Scholar PubMed

[15] Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 2004;287:H1762–70.10.1152/ajpheart.00346.2004Suche in Google Scholar PubMed

[16] Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.10.1038/nm0603-669Suche in Google Scholar PubMed

[17] Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 2013;10:519–30.10.1038/nrcardio.2013.94Suche in Google Scholar PubMed

[18] Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000;86:e29–35.10.1161/01.RES.86.2.e29Suche in Google Scholar

[19] Aase K, von Euler G, Li X, Ponten A, Thoren P, Cao R, et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 2001;104:358–64.10.1161/01.CIR.104.3.358Suche in Google Scholar

[20] Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010;122:1725–33.10.1161/CIRCULATIONAHA.110.957332Suche in Google Scholar PubMed

[21] Chen R, Lee C, Lin X, Zhao C, Li X. Novel function of VEGF-B as an antioxidant and therapeutic implications. Pharmacol Res 2019;143:33–9.10.1016/j.phrs.2019.03.002Suche in Google Scholar PubMed

[22] O’Connell JL, Romano MM, Campos Pulici EC, Carvalho EE, de Souza FR, Tanaka DM, et al. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: a comparison of functional and histopathological changes. Exp Toxicol Pathol 2017;69:213–9.10.1016/j.etp.2017.01.004Suche in Google Scholar PubMed

[23] Xu J-P, Wang H-X, Wang W, Zhang L-K, Tang C-S. Ghrelin improves disturbed myocardial energy metabolism in rats with heart failure induced by isoproterenol. J Pept Sci 2010;16:392–402.10.1002/psc.1253Suche in Google Scholar

[24] Ammar HI, Saba S, Ammar RI, Elsayed LA, Ghaly WB, Dhingra S. Erythropoietin protects against doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2011;301:H2413–21.10.1152/ajpheart.01096.2010Suche in Google Scholar PubMed

[25] Carmichael EB. The median lethal dose (LD50) of pentothal sodium for both young and old guinea pigs and rats. Anesthesiology 1947;8:589–93.10.1097/00000542-194711000-00004Suche in Google Scholar PubMed

[26] Lu J, Yao Y, Dai Q, Ma G, Zhang S, Cao L, et al. Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats. Cardiovasc Diabetol 2012;11:105.10.1186/1475-2840-11-105Suche in Google Scholar PubMed PubMed Central

[27] Antunes E, Borrecho G, Oliveira P, Brito J, Aguas A, Martins dos Santos J. Immunohistochemical evaluation of cardiac connexin43 in rats exposed to low-frequency noise. Int J Clin Exp Pathol 2013;6:1874–9.Suche in Google Scholar

[28] Wu R, Yao P-A, Wang H-L, Gao Y, Yu H-L, Wang L, et al. Effect of fermented Cordyceps sinensis on doxorubicin-induced cardiotoxicity in rats. Mol Med Rep 2018;18:3229–41.10.3892/mmr.2018.9310Suche in Google Scholar PubMed PubMed Central

[29] Ozdogan K, Taskin E, Dursun N. Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. Anadolu Kardiyol Derg 2011;11:3–10.10.5152/akd.2011.003Suche in Google Scholar PubMed

[30] Xiao J, Sun G-B, Sun B, Wu Y, He L, Wang X, et al. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 2012;292:53–62.10.1016/j.tox.2011.11.018Suche in Google Scholar PubMed

[31] Yang C, Wang Y, Liu H, Li N, Sun Y, Liu Z, et al. Ghrelin protects H9c2 cardiomyocytes from angiotensin II-induced apoptosis through the endoplasmic reticulum stress pathway. J Cardiovasc Pharmacol 2012;59:465–71.10.1097/FJC.0b013e31824a7b60Suche in Google Scholar PubMed

[32] Milberg P, Fleischer D, Stypmann J, Osada N, Monnig G, Engelen MA, et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Basic Res Cardiol 2007;102:42–51.10.1007/s00395-006-0609-0Suche in Google Scholar PubMed

[33] Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601–10.10.1161/01.CIR.0000160359.49478.C2Suche in Google Scholar PubMed

[34] Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, et al. Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J 2014;168:503–11.e2.10.1016/j.ahj.2014.06.008Suche in Google Scholar PubMed

[35] Pochhi M, Muddeshwar MG. Serum enzymes markers in myocardial infarction: a study of rural area. ASIAN J Med Sci 2017;8:34–7.10.3126/ajms.v8i2.16313Suche in Google Scholar

[36] Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer. J Pediatr Hematol Oncol 2012;34:589–95.10.1097/MPH.0b013e31826faf44Suche in Google Scholar PubMed

[37] Abdel-Raheem IT, Taye A, Abouzied MM. Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol 2013;113:158–66.10.1111/bcpt.12078Suche in Google Scholar PubMed

[38] Miyata S, Takemura G, Kosai K-I, Takahashi T, Esaki M, Li L, et al. Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol 2010;176:687–98.10.2353/ajpath.2010.090222Suche in Google Scholar PubMed PubMed Central

[39] Yang C, Liu J, Liu K, Du B, Shi K, Ding M, et al. Ghrelin suppresses cardiac fibrosis of post-myocardial infarction heart failure rats by adjusting the activin A-follistatin imbalance. Peptides 2018;99:27–35.10.1016/j.peptides.2017.10.018Suche in Google Scholar PubMed

[40] Wang Q, Sui X, Chen R, Ma P, Teng Y, Ding T, et al. Ghrelin ameliorates angiotensin II-induced myocardial fibrosis by upregulating peroxisome proliferator-activated receptor gamma in young male rats. Biomed Res Int 2018;2018:9897581.10.1155/2018/9897581Suche in Google Scholar PubMed PubMed Central

[41] Li L, Zhang L-K, Pang Y-Z, Pan C-S, Qi Y-F, Chen L, et al. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sin 2006;27:527–35.10.1111/j.1745-7254.2006.00319.xSuche in Google Scholar PubMed

[42] McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep 2018;6:e13699.10.14814/phy2.13699Suche in Google Scholar PubMed PubMed Central

[43] Roell W, Lewalter T, Sasse P, Tallini YN, Choi B-R, Breitbach M, et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 2007;450:819–24.10.1038/nature06321Suche in Google Scholar PubMed

[44] Wang A, Chen F, Xie Y, Guo Z, Yu Y. Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown) 2012;13:511–5.10.2459/JCM.0b013e3283542031Suche in Google Scholar PubMed

[45] Fontes MS, van Veen TA, de Bakker JM, van Rijen HV. Functional consequences of abnormal Cx43 expression in the heart. Biochim Biophys Acta 2012;1818:2020–9.10.1016/j.bbamem.2011.07.039Suche in Google Scholar PubMed

[46] Pecoraro M, Rodriguez-Sinovas A, Marzocco S, Ciccarelli M, Iaccarino G, Pinto A, et al. Cardiotoxic effects of short-term doxorubicin administration: involvement of connexin 43 in calcium impairment. Int J Mol Sci 2017;18:E2121.10.3390/ijms18102121Suche in Google Scholar PubMed PubMed Central

[47] Pecoraro M, Sorrentino R, Franceschelli S, Del Pizzo M, Pinto A, Popolo A. Doxorubicin-mediated cardiotoxicity: role of mitochondrial connexin 43. Cardiovasc Toxicol 2015;15:366–76.10.1007/s12012-014-9305-8Suche in Google Scholar PubMed

[48] Soeki T, Niki T, Uematsu E, Bando S, Matsuura T, Kusunose K, et al. Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein. Heart Vessels 2013;28:795–801.10.1007/s00380-013-0333-2Suche in Google Scholar PubMed